Compare PIPR & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PIPR | INDV |
|---|---|---|
| Founded | 1895 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.7B |
| IPO Year | 2003 | 2014 |
| Metric | PIPR | INDV |
|---|---|---|
| Price | $76.18 | $39.16 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $91.38 | N/A |
| AVG Volume (30 Days) | 556.1K | ★ 2.1M |
| Earning Date | 05-01-2026 | 06-08-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | 54.49 | ★ 8100.00 |
| EPS | ★ 1.87 | 1.67 |
| Revenue | ★ $1,904,217,000.00 | $1,239,000,000.00 |
| Revenue This Year | $12.30 | N/A |
| Revenue Next Year | $13.55 | N/A |
| P/E Ratio | $39.99 | ★ $23.07 |
| Revenue Growth | ★ 24.33 | 4.29 |
| 52 Week Low | $69.16 | $22.22 |
| 52 Week High | $380.26 | $42.81 |
| Indicator | PIPR | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 50.96 | 48.16 |
| Support Level | $75.40 | $38.47 |
| Resistance Level | $77.51 | $41.83 |
| Average True Range (ATR) | 2.84 | 1.61 |
| MACD | 0.09 | -0.17 |
| Stochastic Oscillator | 74.40 | 55.43 |
Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities, and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).